Geoffrey von Maltzahn

VentureLabs Partner

Geoffrey von Maltzahn joined Flagship in 2009 and is a VentureLabs® Partner, where he focuses on inventing technologies and starting companies. He is a founder and inventor of the platform technologies for the VentureLabs® companies Seres Therapeutics (NASDAQ: MCRB), Axcella Health, Indigo, and Kaleido Biosciences. Geoff is currently Chief Executive Officer of Kaleido Biosciences and Chief Technology Officer of Indigo. He previously served as the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109—the first clinically-validated Microbiome Therapeutic—and the generation of the company’s Microbiome Therapeutics™ platform. He was Vice President Discovery of Axcella Health, where he led the discovery of two pharmaconutrient products in clinical testing and the development of the company’s ProNutrein™ platform.

Geoff is an inventor on over 100 patents and applications, including the first clinically-validated microbiome therapeutics for treating diseases of the human microbiome; the first tailored pharmaconutrients that deliver specific combinations of amino acids to treat disease; the first therapeutics that communicate in the body to more effectively find and treat cancer; ‘synthetic biomarkers’ for diagnosing and monitoring complex diseases; ‘nanoantennas’ for ultra-precise laser medicine; new ‘parts’ for nanotechnology; and other technologies to help address problems in biology, chemistry, engineering, and medicine.

He has received over 20 awards and honors for his inventions, including the Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; the Harvard-MIT Martha Gray Prize; and the Randolph G. Wei Award, for MIT’s most outstanding contribution at the interface of life sciences and engineering undergraduate research. Geoff also has had his inventions recognized among the “world’s greatest scientific breakthroughs of today” by Dean Kamen on Planet Green and in the Innovations of the Year by MSNBC.

Geoff was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.

Current Investments

  • Indigo
  • Kaleido BioSciences